Direct-acting antivirals
61 articles
The Impact of Expanded Access to DAAs for Hepatitis C Virus on Patient Outcomes in Canada
A study evaluated the early change in rates of HCV-related hospitalizations overall and HCV-related hospitalizations with hepatocellular carcinoma after expanded access to DAAs in Canada. More
Age, Baseline Fibrosis Can Predict Fibrosis Regression with DAA Use
Fibrosis regression is prevalent among 57% of the cohort and is associated with older age and advanced fibrosis at baseline. More
Community-Based, Point-of-Diagnosis Hepatitis C Treatment Improves Outcomes
Researchers at the University of California, San Francisco, report positive results from the No One Waits study. More
Scale-Up of Direct-Acting Antiviral Treatment in Prisons is Both Cost-Effective and Key to HCV Elimination
A study in Australia evaluated the cost-effectiveness of scaling-up HCV treatment in state-wide prison services incorporating long-term outcomes across custodial and community settings. More
Barriers to a Cure: Study Reveals Global Obstacles to Getting Hep C Treatment
A study provides new evidence regarding the registration and reimbursement of HCV therapies, including restrictions on reimbursement, permitting multicountry analyses and highlighting areas for growth. More
